The p73 gene belongs to the p53 gene family, which also includes p63. 1 The three genes encode proteins with extraordinary similarity at both the structural and functional level. Each member of the family functions as a sequence-specific transcription factor in response to DNA damage and activates pathways involved in the regulation of cell death. 1 Despite these similarities, in vivo inactivation of these genes in the mouse revealed that they are involved in completely different cellular processes. In particular, p53-deficient animals, which are normal at birth, develop a broad range of tumours while they age, thus proving p53 tumour suppressor functions. 1 In contrast, p73 null animals do not develop spontaneous tumours. Instead, they are susceptible to chronic infections and are characterized by abnormalities in the central nervous system, such as hippocampal dysgenesis and hydrocephalus. 2 Lastly, p63 is essential for the development of most epithelia, as p63 null mice lack skin and limbs and die in utero. 3, 4 Importantly, while p53 is inactivated in 50% of human cancers, p63 and p73 are rarely inactivated or mutated. Thus, the role of p63 and p73 in cancer is not obvious.
In spite of these differences, provocative findings suggest that functional interactions can occur among family members. Such interactions are complicated by the multiple p63 and p73 isoforms expressed due to alternative splicing and the presence of two separate promoters. The upstream promoter generates full-length isoforms containing the transactivation domain (TA). By contrast, the downstream promoter produces shorter isoforms lacking the TA domain (DN). The DN isoforms act as dominant-negative proteins on the function of not only TA isoforms but also of p53. 1 The best example of such heterotypic interference was provided by Pozniak et al. 5 who demonstrated that DN-p73b is the only isoform expressed in the developing brain at day 10. In p73 null mice, which lack all the isoforms, p53-dependent apoptosis of developing neurons is greatly enhanced, thus indicating that DN-p73b inhibits p53 function in vivo. While DN isoforms inhibit p53 family members, evidence has been produced that TA isoforms are instead required for p53-dependent cell death and transcription. 6 Nevertheless, this has been recently challenged using a different experimental system, 7 suggesting that functional cooperation among family members varies depending on the cell type and stimuli utilized. Interestingly, a very recent paper by David Lane's group has reported the identification of p53 isoforms, which include DN proteins with potential dominant negative function, thus revealing unexpected degrees of complexity. 8 The notion that DN-p73 isoforms inhibit p53 family members suggests that the presence of these isoforms in tumours may have an impact on clinical outcome and response to therapy. In human cancer, both TA-p73 and DN-p73 are expressed, thus suggesting that a balance between the two may be in place to control cell proliferation and cell death. 1 An interesting paper by Mü ller et al. 9 in this issue of 'Cell Death and Differentiation' attempts to address two fundamental questions: (i) by what mechanisms does DNp73b inhibit cell death induced by chemotherapy? (ii) Does the presence of this isoform correlate with reduced survival in cancer? The authors demonstrate that TA-p73b induces apoptosis by a caspase-dependent mechanism and transcriptionally regulates several genes involved in the control of programmed cell death. In particular, transcription of genes encoding death receptors CD95, TNF-R1, TRAIL-R1, and TRAIL-R2 was induced by TA-p73b. In addition the procaspase 8-binding adapter Fas-associated death domain (FADD) was found to be upregulated. The induction of genes encoding several caspases was also observed. Lastly, the expression of a number of genes involved in the intrinsic pathway was induced. Thus, TA-p73b is able to affect both the intrinsic and the extrinsic apoptotic pathways. Interestingly, TA-p73b induces the expression of CD95 on hepatoma cells and sensitizes these cells to anti-CD95 agonistic antibodies. By contrast, DN-p73b inhibits TA-p73b-dependent transactivation of the CD95 gene and CD95-induced cell death, thus confirming that it can work as a dominant-negative protein (Figure 1) .
Then, the authors analyze the effect of TA-vs DN-p73b on the response to chemotherapy in various cell lines. Expression of TA-p73b is induced by chemotherapeutic drugs such as bleomycin, mitoxantrone, and doxorubicin. Remarkably, overexpression of TA-p73b synergizes with drugs for the induction of cell death and the upregulation of CD95. In contrast, while expression of DN-p73b is also induced upon drug treatment, it inhibits both upregulation of CD95 and cell death. Moreover, DN-p73b blocked mitochondrial depolarization thus demonstrating that both extrinsic and intrinsic pathways are affected by this dominant negative isoform.
The very exciting part that follows is focussed on the potential impact of DN-p73b on survival of hepatocellular carcinoma (HCC) patients and its use as a prognostic marker. One of the major caveats of the field of p73 has always been the lack of reliable antibodies and in particular of isoformspecific antibodies. This has hampered the possibility to evaluate protein expression levels of different p73 isoforms in cancer. Now, the authors of this manuscript employ newly generated antibodies against either TA-or DN-p73 10 and find that 37% of the HCCs displayed overexpression of DN-p73b. There was no correlation between DN-p73b expression and p53 mutation status. The authors then analysed survival of HCCs patients with respect to the presence of DN-p73b, the tumour stage and grade, and concluded that there was a strong association between DN-p73b expression and poor survival. These novel findings argue for an oncogenic role of DN-p73b in HCC. These data require confirmation from other series of HCC and further studies are needed to determine whether overexpression of DN-p73b is detected in other tumours and if this also correlates with poor survival. However, the data highlight two important clinical points. Firstly, they illustrate the increasing challenges in defining chemotherapeutic resistance. Patients who are likely to respond inadequately to conventional therapy should be identified at diagnosis to allow for rational introduction of new therapeutic approaches. In many malignancies, immunohistochemical detection of TP53 expression has been the principle marker of possible resistance to chemotherapy. Similar phenotypes may be generated by other mechanisms such as ATM mutations, and as this paper suggests, expression of specific p73 isoforms. Functional assays on clinical material may be necessary to assess the global p53 status within tumours. 11 Secondly, from the point of view of therapy, there is increasing interest in the TRAIL receptors as therapeutic targets, with agonistic MAbs now entering the clinic. It may be necessary to sensitise some tumour cells for this approach to be successful. 12 Pharmacological manipulation of expression of p73 isoforms may successfully synergise with TRAIL-receptor targeted approaches through upregulation of both the receptors themselves and down-stream apoptotic effector molecules.
The existence of multiple p73 isoforms has rendered the understanding of its function difficult and challenging. At the same time, it might explain the lack of spontaneous tumour formation in p73 null animals, in which all p73 isoforms are absent. In fact, the concomitant inactivation of 'oncogenic' and 'tumour suppressive' isoforms may result in the absence of a tumour phenotype. In order to verify this working model, the field of p73 is urgently in need of isoform-specific knockout animals lacking either TA or DN-p73. These mouse models will be fundamental for the understanding of p73 in vivo functions and, in particular, of its role in cancer development. Another important question that remains to be answered is how p73 upstream and downstream promoters are regulated, and whether they are misregulated in cancer. It is known that p73 downstream promoter, which drives the expression of DN-p73, contains a p53 responsive element, which is regulated by both p53 and TA-p73. However, both p53 and TA-p73 expression levels are often very low in primary cells such as mouse embryo fibroblasts, where DN-p73 is instead expressed at quite high levels. This suggests that the p53(p73)/DN-p73 autoregulatory loop is not the only mechanism in place to regulate DN-p73 expression in vivo. Moreover, it is still unclear what mechanisms regulate DN-p73 stability and whether these are different from the ones controlling TAp73 protein levels. Another important question is whether overexpression of DN-p73 can exert tumourigenic activities in vivo and what tissues are susceptible to its action. These are just few of the future challenges awaiting researchers involved in the understanding of the physiological functions of p63 and p73 family members and their role in cancer.
